These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28126299)

  • 1. Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials.
    Holch P; Henry AM; Davidson S; Gilbert A; Routledge J; Shearsmith L; Franks K; Ingleson E; Albutt A; Velikova G
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):495-510. PubMed ID: 28126299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of Radiation Therapy Toxicity Reporting in Randomized Controlled Trials of Rectal Cancer: A Comparison of Patient-Reported Outcomes and Clinician Toxicity Reporting.
    Gilbert A; Ziegler L; Martland M; Davidson S; Efficace F; Sebag-Montefiore D; Velikova G
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):555-67. PubMed ID: 26068490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    Protopapa E; van der Meulen J; Moore CM; Smith SC
    BJU Int; 2017 Oct; 120(4):468-481. PubMed ID: 28437031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making.
    Van Hemelrijck M; Sparano F; Moris L; Beyer K; Cottone F; Sprangers M; Efficace F
    Cancer Med; 2020 Jun; 9(12):4039-4058. PubMed ID: 32333639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy: A Systematic Review.
    Fabian A; Domschikowski J; Letsch A; Schmalz C; Freitag-Wolf S; Dunst J; Krug D
    JAMA Netw Open; 2022 Sep; 5(9):e2231930. PubMed ID: 36136335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G).
    Smith AB; Cocks K; Parry D; Taylor M
    Qual Life Res; 2014 Apr; 23(3):971-6. PubMed ID: 24097080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials.
    Kee DLC; Gal J; Falk AT; Schiappa R; Chand ME; Gautier M; Doyen J; Hannoun-Levi JM
    Cancer Treat Rev; 2018 Nov; 70():265-271. PubMed ID: 30326422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications.
    Stefanovic S; Wallwiener M; Karic U; Domschke C; Katic L; Taran FA; Pesic A; Hartkopf A; Hadji P; Teufel M; Schuetz F; Sohn C; Fasching P; Schneeweiss A; Brucker S
    Support Care Cancer; 2017 Feb; 25(2):549-558. PubMed ID: 27747478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
    Gilbert A; Piccinin C; Velikova G; Groenvold M; Kuliś D; Blazeby JM; Bottomley A
    J Clin Oncol; 2022 Nov; 40(32):3770-3780. PubMed ID: 35973158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
    Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Reported Outcomes Following Magnetic Resonance-Guided Radiation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Westerhoff JM; Lalmahomed TA; Meijers LTC; Henke L; Teunissen FR; Bruynzeel AME; Alongi F; Hall WA; Kishan AU; Intven MPW; Verkooijen HM; van der Voort van Zyp JRN; Daamen LA
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):38-48. PubMed ID: 38838994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group.
    Berthelsen DB; Woodworth TG; Goel N; Ioannidis JPA; Tugwell P; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Leong AL; Conaghan PG; Boers M; Shea BJ; Brooks PM; Simon LS; Furst DE; Christensen R;
    Semin Arthritis Rheum; 2021 Jun; 51(3):607-617. PubMed ID: 33483129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
    David R; Buckby A; Kahokehr AA; Lee J; Watson DI; Leung J; O'Callaghan ME
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):8-15. PubMed ID: 35260794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials.
    Efficace F; Fayers P; Pusic A; Cemal Y; Yanagawa J; Jacobs M; la Sala A; Cafaro V; Whale K; Rees J; Blazeby J;
    Cancer; 2015 Sep; 121(18):3335-42. PubMed ID: 26079197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
    Basch E; Rogak LJ; Dueck AC
    Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
    JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Kluetz PG; Chingos DT; Basch EM; Mitchell SA
    Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.